# Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial

> **NCT03699904** · PHASE2 · TERMINATED · sponsor: **Belfast Health and Social Care Trust** · enrollment: 85 (actual)

## Conditions studied

- COPD
- EBV

## Interventions

- **DRUG:** Valaciclovir
- **DRUG:** Placebo capsules (containing Avicel blend)

## Key facts

- **NCT ID:** NCT03699904
- **Lead sponsor:** Belfast Health and Social Care Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-11
- **Primary completion:** 2020-05-07
- **Final completion:** 2020-07-01
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** In light of the evolving Covid19 pandemic ongoing study recruitment was felt to pose an unacceptable risk to patient safety.
- **Last updated:** 2020-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699904, "Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03699904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*